Related Experiment Video

Updated: Jun 24, 2025

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

9.8K

Potential Mechanism by which Eriodictyol Protects against Doxorubicininduced Cardiotoxicity based on Network

Chunmeng Qin1,2, Mei Sun1, Feng Lv1

  • 1Department of Pharmacy, The Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, China.

Current Computer-Aided Drug Design
|June 7, 2024
PubMed
Abstract

Insights

Eriodictyol (ERD) may protect against doxorubicin-induced cardiotoxicity (DIC) by targeting multiple pathways, particularly the ROS pathway. This study elucidates ERD's protective mechanisms for potential clinical use.

Area of Science:

  • Pharmacology
  • Computational Biology
  • Cardiovascular Research

Background:

  • Doxorubicin (DOX) is a vital chemotherapy drug, but its use is limited by cardiotoxicity (DIC).
  • Eriodictyol (ERD) exhibits cardioprotective properties, yet its mechanism against DIC remains unclear.

Purpose of the Study:

  • To investigate the underlying mechanisms of eriodictyol's protective effects against doxorubicin-induced cardiotoxicity.
  • To identify key molecular targets and pathways involved in ERD's cardioprotection.

Main Methods:

  • Utilized network pharmacology by integrating data from multiple databases (TCMSP, PharmMaper, etc.) to identify ERD and DIC targets.
  • Constructed a protein-protein interaction network and performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses.
  • Validated interactions using molecular docking and molecular dynamics simulations.

Main Results:

  • Identified 43 intersecting ERD-DIC targets, highlighting 6 key targets.
  • Functional enrichment analysis revealed significant involvement in biological processes, cellular components, and molecular functions.
  • Molecular docking and dynamics simulations confirmed strong binding affinities between ERD and critical targets, especially within the ROS pathway.

Conclusions:

  • Systematic network pharmacology analysis suggests ERD mitigates DIC via multiple targets and pathways.
  • The ROS pathway is identified as a potentially crucial mediator of ERD's cardioprotective effects.
  • Findings offer a foundation for further research and clinical application of ERD in managing DIC.
Keywords:
Eriodictyolcardiotoxicitydoxorubicinmolecular dockingnetwork pharmacologyreactive oxygen species.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.5K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.8K

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
969
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421